Off to market: Boxes go on display of the Huier Kangxin quadrivalent subunit influenza vaccine. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]
The new Huier Kangxin quadrivalent subunit influenza vaccine developed by Ab&B Bio-tech Co Ltd – based in the Taizhou Medical High-tech Zone in Taizhou city, East China's Jiangsu province – recently got the green light to go on the market.
It is being sold exclusively nationwide and will now be quickly shipped to the whole country.
As a brand-new third-generation influenza vaccine, the product is said to have multiple quality standards higher than those of the Chinese and European pharmacopoeia, reaching the advanced level worldwide.
The manufacturer says the listing of Huier Kangxin will provide better options for vaccination during the flu season in 2024-25 and contribute to influenza prevention and control work.
Founded in 2015, Ab&B Bio-tech Co is involved in the production, research and development, registration and sales of human vaccines.
The company says its subunit influenza vaccines cover the needs of various groups of people.
To date, Ab&B Bio-tech Co has obtained multiple clinical approvals for new drugs and it is currently conducting a number of clinical trials and NDA, or new drug applications.